This trial will study whether the drug obinutuzumab is safe and effective in treating adolescent patients with lupus nephritis.
1 Primary · 15 Secondary · Reporting Duration: Baseline, Weeks 4, 24, 52 and 76
Experimental Treatment
Non-Treatment Group
30 Total Participants · 2 Treatment Groups
Primary Treatment: Obinutuzumab · Has Placebo Group · Phase 2
Age 12 - 17 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:California | 100.0% |
18 - 65 | 100.0% |
University of California San Francisco | 100.0% |
Met criteria | 100.0% |